High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.
Aim was to investigate the propensity to switch to long-acting injectable HIV pre-exposure prophylaxis (PrEP) with cabotegravir among oral PrEP-experienced men who have sex with men. Out of 377 PrEP users, 325 (86.2%) were interested (would like = 210) or considering (would consider = 115) switch to long-acting PrEP. At multivariable analysis, the odds ratio of interest in long-acting PrEP in non-adherent vs. adherent individuals to oral PrEP was 5.03 (95%CI = 1.73-14.61,p = 0.003) and of consideration 1.63 (95%CI = 0.51-5.23,p = 0.410). We observed very high propensity to switch to long-acting PrEP, particularly among non-adherent users. Rapid availability of long-acting PrEP might address unmet needs of PrEP users in Italy.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/NEJMoa2101016 .
[DOI: 10.1056/NEJMoa2101016]
Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554–62. https://doi.org/10.1016/S2352-3018(22)00133-3 .
[DOI: 10.1016/S2352-3018(22)00133-3]
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60. https://doi.org/10.1016/S0140-6736(15)00056-2 .
[DOI: 10.1016/S0140-6736(15)00056-2]
Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166–74. https://doi.org/10.1016/S2352-3018(20)30271-X .
[DOI: 10.1016/S2352-3018(20)30271-X]
Girometti N, McCormack S, Tittle V, McOwan A, Whitlock G, 56 Dean Street Collaborative Group. Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. AIDS. 2022;36(4):561–6. https://doi.org/10.1097/QAD.0000000000003143 .
[DOI: 10.1097/QAD.0000000000003143]
Jourdain H, de Gage SB, Desplas D, Dray-Spira R. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. Lancet Public Health. 2022;7(6):e529–36. https://doi.org/10.1016/S2468-2667(22)00106-2 .
[DOI: 10.1016/S2468-2667(22)00106-2]
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. https://doi.org/10.1016/S0140-6736(20)32666-0 .
[DOI: 10.1016/S0140-6736(20)32666-0]
Akinwunmi B, Buchenberger D, Scherzer J, Bode M, Rizzini P, Vecchio F, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four european countries. Sex Transm Infect. 2021;97(8):566–73. https://doi.org/10.1136/sextrans-2020-054648 .
[DOI: 10.1136/sextrans-2020-054648]
Alberton F, Nozza S, Raccagni AR, Galli L, Spagnuolo V, Bossolasco S, et al. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment. J Med Virol. 2023;95(1):e28330. https://doi.org/10.1002/jmv.28330 .
[DOI: 10.1002/jmv.28330]
Fonner VA, Ridgeway K, van der Straten A, Lorenzetti L, Dinh N, Rodolph M, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957–66. https://doi.org/10.1097/QAD.0000000000003494 .
[DOI: 10.1097/QAD.0000000000003494]
Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–7. https://doi.org/10.1097/QAI.0b013e318256b2f6 .
[DOI: 10.1097/QAI.0b013e318256b2f6]
Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study. J Int AIDS Soc. 2023;26(3):e26077. https://doi.org/10.1002/jia2.26077 .
[DOI: 10.1002/jia2.26077]
Jones MD, Jones K, Almirol E, Payne G, Graves B, Schneider JA, et al. Examining the awareness, acceptability, and adoption of conventional and non-conventional forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among jail-involved black sexual minority men (BSMM) and black Transgender Women (BTW) in two diverse US Cities. AIDS Behav. 2023;27(4):1304–13. https://doi.org/10.1007/s10461-022-03866-4 .
[DOI: 10.1007/s10461-022-03866-4]
Pedrana L, Magno L, Zucchi EM, da Silva LAV, Ferraz D, Grangeiro A, et al. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil. BMC Public Health. 2022;22(1):1728. https://doi.org/10.1186/s12889-022-14134-4 .
[DOI: 10.1186/s12889-022-14134-4]
Beckham SW, Mantsios A, Galai N, Likindikoki S, Mbwambo J, Davis W, Kerriet al, et al. Acceptability of multiple modalities of pre-exposure prophylaxis (PrEP) among female sex workers in Tanzania: a mixed-methods study. BMJ Open. 2022;12(8):e058611. https://doi.org/10.1136/bmjopen-2021-058611 .
[DOI: 10.1136/bmjopen-2021-058611]
Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and other PrEP modalities among sexual minority men in Nigeria, Africa. AIDS Behav. 2022;26(7):2363–75. https://doi.org/10.1007/s10461-022-03575-y .
[DOI: 10.1007/s10461-022-03575-y]
John SA, Zapata JP, Dang M, Pleuhs B, O’Neil A, Hirshfield S, et al. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old. Sci Rep. 2023;13(1):5116. https://doi.org/10.1038/s41598-023-32014-8 .
[DOI: 10.1038/s41598-023-32014-8]
Torres TS, Nascimento AR, Coelho LE, Konda KA, Vega-Ramirez EH, Elorreaga OA, et al. Preferences for PrEP modalities among gay, bisexual, and other men who have sex with men from Brazil, Mexico, and Peru: a cross-sectional study. Ther Adv Infect Dis. 2023;10:20499361231153548. https://doi.org/10.1177/20499361231153548 .
[DOI: 10.1177/20499361231153548]
Wray TB, Chan PA, Klausner JD, Ward LM, Ocean EMS. Gay, bisexual, and other men who have sex with Men who are not on oral PrEP may be less interested in available Injectable Products than in oral PrEP: examining individual-level determinants of interest and barriers across products. AIDS Behav. 2022;26(11):3794–805. https://doi.org/10.1007/s10461-022-03708-3 .
[DOI: 10.1007/s10461-022-03708-3]
Chan C, Vaccher S, Fraser D, Grulich AE, Holt M, Zablotska-Manos I, et al. Preferences for current and future PrEP modalities among PrEP-Experienced gay and bisexual men in Australia. AIDS Behav. 2022;26(1):88–95. https://doi.org/10.1007/s10461-021-03344-3 .
[DOI: 10.1007/s10461-021-03344-3]
